Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus

被引:28
作者
Brandman, Danielle [1 ]
Pingitore, Andrea [4 ]
Lai, Jennifer C. [1 ]
Roberts, John P. [2 ]
Ferrell, Linda [3 ]
Bass, Nathan M. [1 ]
Terrault, Norah A. [1 ]
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[4] Alameda Cty Med Ctr, Dept Pathol, Oakland, CA USA
关键词
INSULIN-RESISTANCE; METABOLIC SYNDROME; DIABETES-MELLITUS; NONALCOHOLIC STEATOHEPATITIS; CARDIOVASCULAR-DISEASE; NATURAL-HISTORY; PROGRESSION; ASSOCIATION; CIRRHOSIS; THERAPY;
D O I
10.1002/lt.22389
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Recurrent hepatitis C virus (HCV) is the most common cause of graft loss for HCV-infected recipients of liver transplantation (LT). Diabetes mellitus (DM) has been associated with increased rates of fibrosis progression, but whether steatosis affects post-LT outcomes independently of DM is unclear. Using a retrospective cohort of HCV-infected LT recipients, we determined the prevalence of hepatic steatosis and evaluated the relationship between steatosis on index biopsy 1 year after LT (+/- 6 months) and the severity of the subsequent fibrosis. One hundred fifty-two LT recipients with HCV were followed up for a median of 2.09 years (range = 0.13-6.17 years) after index biopsy; the median number of biopsy procedures per patient after index biopsy was 2 (range = 1-6). Steatosis (>= 5%) was present in 45 individuals (29.6%) according to index biopsy samples taken 1 year after LT; the steatosis was mild (grade 1) in 80% of the patients. In the multivariate analysis, the presence of steatosis 1 year after LT was positively associated with HCV genotype 3 [odds ratio (OR) = 3.60, P = 0.02], older donor age (OR = 1.03, P = 0.04), and pre-LT hypertension (OR = 3.29, P = 0.009). Two years after index biopsy, the cumulative rate of significant fibrosis (F2-F4 on the Ludwig-Batts scale) was 49% in the patients with steatosis at 1 year and 24% in the patients without steatosis (P = 0.003). In the multivariate analysis, steatosis at 1 year was an independent predictor of subsequent F2 to F4 fibrosis (HR = 2.63, 95% CI = 1.49-4.63). Steatosis was a stronger predictor of fibrosis in the setting of sirolimus use (hazard ratio = 9.38, 95% confidence interval = 1.37-64.16, P = 0.02). In conclusion, steatosis is frequent in the early post-LT period, and steatosis within the first year after LT is a marker of a higher risk of fibrosis progression in HCV-infected patients. Liver Transpl, 2011. (C) 2011 AASLD.
引用
收藏
页码:1380 / 1386
页数:7
相关论文
共 34 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]   Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity [J].
Adinolfi, LE ;
Gambardella, M ;
Andreana, A ;
Tripodi, MF ;
Utili, R ;
Ruggiero, G .
HEPATOLOGY, 2001, 33 (06) :1358-1364
[3]   Post-liver transplantation diabetes mellitus: An association with hepatitis C [J].
AlDosary, AA ;
Ramji, AS ;
Elliott, TG ;
Sirrs, SM ;
Thompson, DM ;
Erb, SR ;
Steinbrecher, UP ;
Yoshida, EM .
LIVER TRANSPLANTATION, 2002, 8 (04) :356-361
[4]   CHRONIC HEPATITIS - AN UPDATE ON TERMINOLOGY AND REPORTING [J].
BATTS, KP ;
LUDWIG, J .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (12) :1409-1417
[5]   Adipose tissue, inflammation, and cardiovascular disease [J].
Berg, AH ;
Scherer, PE .
CIRCULATION RESEARCH, 2005, 96 (09) :939-949
[6]   Impact of Donor Graft Steatosis on Overall Outcome and Viral Recurrence After Liver Transplantation for Hepatitis C Virus Cirrhosis [J].
Briceno, Javier ;
Ciria, Ruben ;
Pleguezuelo, Maria ;
de la Mata, Manuel ;
Muntane, Jordi ;
Naranjo, Alvaro ;
Sanchez-Hidaigo, Juan ;
Marchal, Trinidad ;
Rufian, Sebastian ;
Lopez-Cillero, Pedro .
LIVER TRANSPLANTATION, 2009, 15 (01) :37-48
[7]   Rapamycin Inhibits Hepatic Fibrosis in Rats by Attenuating Multiple Profibrogenic Pathways [J].
Bridle, Kim R. ;
Popa, Claudia ;
Morgan, Maelle L. ;
Sobbe, Amy L. ;
Clouston, Andrew D. ;
Fletcher, Linda M. ;
Crawford, Darrell H. G. .
LIVER TRANSPLANTATION, 2009, 15 (10) :1315-1324
[8]   Donor Livers with Steatosis Are Safe To Use in Hepatitis C Virus-Positive Recipients [J].
Burra, Patrizia ;
Loreno, Massimiliano ;
Russo, Francesco Paolo ;
Germani, Giacomo ;
Galligioni, Alessandra ;
Senzolo, Marco ;
Cillo, Umberto ;
Zanus, Giacomo ;
Fagiuoli, Stefano ;
Rugge, Massimo .
LIVER TRANSPLANTATION, 2009, 15 (06) :619-628
[9]   Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation [J].
Cotler, Scott J. ;
Kallwitz, Eric ;
TenCate, Veronica ;
Bhushan, Anita ;
Berkes, Jamie ;
Benedetti, Enrico ;
Layden-Almer, Jennifer ;
Layden, Thomas J. ;
Valyi-Nagy, Tibor ;
Guzman, Grace .
TRANSPLANTATION, 2007, 84 (05) :587-591
[10]   Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C [J].
Cua, Ian Homer Y. ;
Hui, Jason M. ;
Kench, James G. ;
George, Jacob .
HEPATOLOGY, 2008, 48 (03) :723-731